The NRF2/ARE signalling pathway is a key mediator in oxidative stress and therefore a potential target for neuroprotective agents. The publication describes the identification of nonacidic tetrahydroisoquinolines (THIQs) that inhibit the interaction between NRF2 and its main negative regulator KEAP1.…
Carlo joins other leading authorities in drug discovery and development as part of the Biopharmaceuticals category in the Medicine Maker Power List. In his interview he reviews future trends in drug development and some of the defining moments of his…
IRBM and their collaborators’ at the universities of Strasbourg and Siena have recently published a paper in the ACS Medicinal Chemistry Letters which describes their approach to the identification of a 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new…
IRBM’s Chief Science Officer, Carlo Toniatti is once again featured in the Medicine Maker. This time he takes us on a journey from the clinic, to academia, to industry – where he spent over two decades developing anti-cancer drugs. Carlo…
Our Chief Scientific Officer, Carlo Toniatti, has been featured in The Medicine Maker, where he explored how we can catalyse the discovery and development of oncology drugs. In the article, he discusses how to overcome the challenges in developing efficacious…
In an original research publication for the current issue of Frontiers in Neuroscience, IRBM and collaborators developed and applied novel ultrasensitive immunoassays to enable detection of synuclein and S129 phosphorylated synuclein in clinical samples. The new research demonstrated that S129…